Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

This post was originally published on this site

Nov 29 Novo Nordisk’s long-acting insulin blockbuster Tresiba has a safe cardiovascular profile in patients with type 2 diabetes, results released by the company on Tuesday showed. The so-called DEVOTE study, involving more than 7,500 patients, demonstrated Tresiba’s non-inferiority of major adverse cardiovascular events to rival Sanofi’s long-acting insulin Lantus , the Novo statement said.